Amgen (AMGN) Stock Sinks As Market Gains: Here's Why

In the latest trading session, Amgen (AMGN) closed at $294.12, marking a -1.27% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.37%. Elsewhere, the Dow saw a downswing of 0.14%, while the tech-heavy Nasdaq appreciated by 0.71%. Shares of the world's largest biotech drugmaker have appreciated by 5.02% over the course of the past month, underperforming the Medical sector's gain of 5.9%, and outperforming the S&P 500's gain of 4.26%.Investors will be eagerly watching for the performance of Amgen in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 4, 2025. The company's earnings per share (EPS) are projected to be $5.01, reflecting a 10.22% decrease from the same quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $8.93 billion, indicating a 5.04% growth compared to the corresponding quarter of the prior year. For the full year, the Zacks Consensus Estimates project earnings of $21.1 per share and a revenue of $35.66 billion, demonstrating changes of +6.35% and +6.69%, respectively, from the preceding year. Investors might also notice recent changes to analyst estimates for Amgen. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Amgen is currently a Zacks Rank #3 (Hold). Investors should also note Amgen's current valuation metrics, including its Forward P/E ratio of 14.12. This denotes a discount relative to the industry average Forward P/E of 19.52. It's also important to note that AMGN currently trades at a PEG ratio of 2.59. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.89. The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 79, finds itself in the top 32% echelons of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amgen Inc. (AMGN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks